New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
10:40 EDTMNK, QCORShort-seller target Questcor spikes after deal to be bought by Mallinckrodt
Questcor (QCOR) shares are sharply higher this morning after the company agreed to be bought by Mallinckrodt (MNK) in a transaction valued at approximately $5.6B. WHAT'S NEW: Questcor, a biopharmaceutical company whose primary drug, H.P. Acthar Gel, is approved by the FDA for the treatment of 19 indications, will be acquired by Mallinckrodt for about $5.6B, made up of $30.00 per share in cash and 0.897 Mallinckrodt shares for each Questcor share they own. The total consideration equated to approximately $86.10 per Questcor share based on the closing price of Mallinckrodt shares on April 4. After the deal closes, Mallinckrodt shareholders will own approximately 50.5% and former Questcor shareholders will own approximately 49.5% of the combined company's stock. The deal is expected to immediately add to Mallinckrodt's fiscal 2014 adjusted earnings per share and significantly add to fiscal 2015 adjusted EPS. The transaction is targeted to close in the third quarter. On the companies' conference call discussing the merger, Questcor said it believes that its first quarter sales will be "somewhat lower" than the fourth quarter of 2013, but also "substantially higher" than last year's first quarter; the consensus estimate for Q1 revenue is $242.08M. Questcor also said that it sees a "favorable" tax structure and operating cash flow, as well as immediate value for shareholders. Mallinckrodt said sees about a 10% decline in the tax rate with the Questcor deal and believes it will realize immediate tax benefits. Mallinckrodt added that its focus will be on deleveraging in the coming months to allow for strategic acquisitions. WHAT'S NOTABLE: Of the 19 indications approved for Acthar, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. Questcor has been a frequent target of the short-selling blog Citron Research in the past. As recently as March 14, Citron Research claimed Questcor was "deceiving" the FDA and investors, alleging H.P. Acthar Gel's active ingredient is less than 20% of the label specification. PRICE ACTION: Questcor is trading up $11.48, or 16.91%, to $79.35 in mid-morning trading. Meanwhile, Mallinckrodt is down $1.70, or 2.72%, to $60.82.
News For QCOR;MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
10:25 EDTMNKOptions with decreasing implied volatility
Subscribe for More Information
08:46 EDTMNKMallinckrodt price target lowered to $82 from $97 at Leerink
Leerink analyst Jason Gerberry says Mallinckrodt reported a strong Q4 for Acthar. The analyst wants to see a few more quarters of outperformance, however, before adjusting his estimates. He lowered his price target for Mallinckrodt to $82 citing the group rerating and keeps an Outperform rating on the name.
November 23, 2015
09:18 EDTMNKOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Tyson Foods (TSN), up 2.4%... Mallinckrodt (MNK), up 7.4%. ALSO HIGHER: Novocure (NVCR), up 16.8% after announcing new Phase 3 data from Optune study... CTI BioPharma (CTIC), up 12.7% after the initiation of its rolling new drug application to the FDA for pacritinib... Peabody Energy (BTU), up 14.8% after announcing an asset sale... Sarepta Therapeutics (SRPT), up 5.2% following a positive mention in Barron's. DOWN AFTER EARNINGS: Trina Solar (TSL), down 5.6%. ALSO LOWER: Par Pacific (PARR), down 13.2% after pricing its 3.4M registered direct offering at $22.00... Lions Gate (LGF), down 2.9% after the "Hunger Games" finale opens below the series average.
06:12 EDTMNKValeant questions spread to similar drug companies, WSJ says
Subscribe for More Information
06:03 EDTMNKMallinckrodt reports Q4 adjusted EPS $1.84, consensus $1.77
Subscribe for More Information
November 20, 2015
07:22 EDTMNKMallinckrodt price target lowered to $85 from $130 at Jefferies
Subscribe for More Information
November 19, 2015
09:04 EDTMNKMallinckrodt authoizes $500M expansion to share repurchase program
Mallinckrodt has authorized an incremental $500M share repurchase program. The new authorization permits the company to repurchase up to $500M of Mallinckrodt plc ordinary shares. This new authorization supplements the roughly $200M remaining from the previously authorized share repurchase plan announced in January. Mallinckrodt also authorized management to reduce the company's outstanding debt at its discretion. Both the share repurchase and debt reduction programs are open-ended in time, and based on Mallinckrodt's expected capacity to generate durable earnings and approximately $1B in annual cash flow.
09:02 EDTMNKMallinckrodt board adds $500M to existing share repurchase program
Subscribe for More Information
08:58 EDTMNKMallinckrodt trading halted, pending news
Subscribe for More Information
November 18, 2015
12:06 EDTMNKDrug at center of new pricing concern immaterial to Mallinckrodt, says Northland
Subscribe for More Information
05:51 EDTMNKMallinckrodt price increase raises new questions, WSJ says
Subscribe for More Information
05:39 EDTMNKMallinckrodt raised infant seizure drug price by 2,000%, CBC reported
Subscribe for More Information
November 16, 2015
07:36 EDTMNKMallinckrodt receives FDA clearance for INOmax DSIR plus MRI device
Mallinckrodt announced that the U.S. FDA has cleared INOmax DSIR Plus MRI device for delivery of INOMAX for inhalation during MRI procedures. The INOmax DSIR Plus MRI delivery system is indicated for delivery of INOMAX for inhalation therapy gas into the patient-breathing circuit to provide a constant concentration of nitric oxide to the patient. The INOmax DSIR Plus MRI is indicated for use only with Magnetic Resonance Conditional ventilators validated to be compatible, as identified in the device labeling. The FDA clearance is based on the determination of Substantial Equivalence to the INOmax DSIR. The modifications to INOmax DSIR for the INOmax DSIR Plus MRI device included hardware modifications to the cart, an update of the software to include an MRI set-up wizard and modified labeling. The INOmax DSIR Plus MRI has the same intended therapeutic effect and patient population as the previously cleared INOmax DSIR predicate device.
November 13, 2015
10:50 EDTMNKOptions with increasing implied volatility
Subscribe for More Information
November 12, 2015
10:50 EDTMNKOptions with increasing implied volatility
Options with increasing implied volatility: FTK MW NLNK MNK GOGO LULU RAD FL

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use